Evidence map›Paper›PMID 36285482›Full record

ArticleCancer science2023

Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation.

Hiroki Komatsuda, Risa Wakisaka, Michihisa Kono, Takumi Kumai, Ryusuke Hayashi, Hidekiyo Yamaki, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Hiroki KomatsudaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.ORCID https://orcid.org/0000-0002-3783-2746
Risa WakisakaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Michihisa KonoDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Takumi KumaiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.ORCID https://orcid.org/0000-0002-3411-671X
Ryusuke HayashiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Hidekiyo YamakiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Ryosuke SatoDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Toshihiro NagatoDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Takayuki OhkuriDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.ORCID https://orcid.org/0000-0002-6889-7809
Akemi KosakaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Kenzo OharaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Miki TakaharaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Akihiro KatadaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Hiroya KobayashiDepartment of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Asahikawa Medical University · JP

Funding

Japan Society for the Promotion of Science 20K09724
6 · The paper itself

Abstract

Homeobox B7 (HOXB7) is a master regulatory gene that regulates cell proliferation and activates oncogenic pathways. Overexpression of HOXB7 correlates with aggressive behavior and poor prognosis in patients with cancer. However, the expression and role of HOXB7 in head and neck squamous cell carcinoma (HNSCC) remain unclear. In this study, we observed that most samples from patients with oropharyngeal cancer and HNSCC expressed HOXB7. As no direct inhibitor has been reported, we identified a potent peptide epitope to target HOXB7-expressing tumors through immune cells. A novel HOXB7-derived peptide epitope (HOXB7

Indexed as

Genes, HomeoboxHead and Neck NeoplasmsEpitopesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHomeodomain ProteinsHumansMitogen-Activated Protein KinasesSquamous Cell Carcinoma of Head and NeckT-LymphocytesUp-RegulationEpitopesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHomeodomain ProteinsHOXB7 protein, humanMitogen-Activated Protein Kinasescancer immunotherapyHLAHOXB7MAPKpeptide vaccine

Identifiers

PMID36285482
PMCPMC9899601
OpenAlexW4307341140

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.